Sitagliptin (Januvia™) is a new oral agent ... including T-cell activation and proliferation. Although the mechanism of action may indicate that DPP-4 inhibition is a promising treatment for ...

Objective: To examine the efficacy and safety of once-daily oral sitagliptin as monotherapy in patients with type 2 diabetes. Research Design and Methods: In a randomized, double-blind ...